Abingworth Bioventures 9 LP — Form D/A
Abingworth Bioventures 9 LP of WASHINGTON, DC, a pooled investment fund, filed a Form D amendment with the SEC on 2025-12-19. $320.3M was reported sold. Industry: Pooled Investment Fund.
Offering
- Filed: 2025-12-19
- Form: D/A
- Accession: 0001986435-25-000002
- Industry: Pooled Investment Fund
- Exemptions: 06b, 3C, 3C.7
- Amount sold: $320.3M
- Investors: 29
- Date of first sale: 2023-12-22
- Security types: fund interests
- Revenue range: Decline to Disclose
- SEC file number: 021-500399
Issuer
- Name: Abingworth Bioventures 9 LP
- CIK: 0001986435
- Entity type: Limited Partnership
- Jurisdiction: DELAWARE
- Incorporated: 2023
- Address: 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON, DC, 20004
- Phone: 202-729-5626
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Jeremy Anderson | Executive Officer | Washington, DC |
| Christina Gibbs | Executive Officer | Washington, DC |
| David Lobe | Executive Officer | Washington, DC |
| Robert Rosen | Executive Officer | Washington, DC |
| N/A ABV 9 GP LP | Promoter | Washington, DC |
| N/A ABV 9 Holdings, L.L.C. | Promoter | Washington, DC |
| Elizabeth Muscarella | Executive Officer | New York, NY |
| Rob Rosen | Executive Officer | Washington, DC |
Other filings by this issuer (2)
More